Effect of 12-Week BMI-Based Vitamin D 3 Supplementation in Parkinson's Disease with Deep Brain Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites.
Zofia Kinga BytowskaDaria KorewoPaweł BerezkaKonrad KowalskiKatarzyna PrzewłóckaWitold LibionkaWojciech KlocJan Jacek KaczorPublished in: International journal of molecular sciences (2023)
Parkinson's disease (PD) is the second most common neurodegenerative disease. To manage motor symptoms not controlled adequately with medication, deep brain stimulation (DBS) is used. PD patients often manifest vitamin D deficiency, which may be connected with a higher risk of falls. We administered a 12-week vitamin D 3 supplementation based on BMI (with higher doses given to patients with higher BMI) to investigate its effects on physical performance and inflammation status in PD patients with DBS. Patients were randomly divided into two groups: treated with vitamin D 3 (VitD, n = 13), and supplemented with vegetable oil as the placebo group (PL, n = 16). Patients underwent functional tests to assess their physical performance three times during this study. The serum 25(OH)D 3 concentration increased to the recommended level of 30 ng/mL in the VitD group, and a significant elevation in vitamin D metabolites in this group was found. We observed significant improvement in the Up and Go and the 6 MWT in the VitD group. In inflammation status, we noticed a trend toward a decrease in the VitD group. To conclude, achieving the optimal serum 25(OH)D 3 concentration is associated with better functional test performance and consequently may have a positive impact on reducing falling risk in PD.
Keyphrases
- deep brain stimulation
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- parkinson disease
- oxidative stress
- mental health
- body mass index
- prognostic factors
- obsessive compulsive disorder
- randomized controlled trial
- ms ms
- healthcare
- clinical trial
- emergency department
- depressive symptoms
- fatty acid
- placebo controlled
- adverse drug